Business Context and Reporting Period
Company: Redhill Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: December 30, 2013
Context: The Company announced a definitive agreement for a private placement transaction with OrbiMed Israel Partners Limited Partnership to raise capital for general working capital and research and development, specifically for Phase III clinical studies of RHB-104 (Crohn's disease) and RHB-105 (H. pylori infection).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, or existing debt levels. The document focuses exclusively on the terms of a new financing event.
| Metric | Value |
|---|---|
| Total Financing Amount | $6.0 million |
| Units Issued | 631,580 Units (1 ADS + 0.4 Warrant per Unit) |
| Price Per Unit | $9.50 |
| Warrant Exercise Price | $11.00 per ADS |
| Warrant Term | 3 years |
| Expected Closing Date | On or before January 9, 2014 |
Material Changes
This filing represents a material change in the Company's capital structure through the issuance of new equity and warrants. The transaction introduces a "full ratchet" anti-dilution provision: if the Company issues additional securities at a price below $9.50 before raising an aggregate of $28 million, OrbiMed will receive additional ADSs to reduce their effective purchase price to the lower subsequent offering price.
Guidance, Outlook, and Risks
- Use of Proceeds: Funds will be utilized for general working capital and R&D, specifically advancing Phase III studies for gastrointestinal programs.
- Registration Obligations: The Company must file a registration statement for the ADSs and warrants. The agreement includes liquidated damages if filing deadlines are missed or if the registration statement does not remain effective as required.
- Change in Control: In a cash-only change of control, warrants will be cancelled and the holder will receive the cash equivalent of immediate exercise. In other transactions, the successor entity must assume the warrant obligations.
- Risks: The transaction is subject to customary closing conditions. The anti-dilution provision may significantly impact future capital raising flexibility if the share price declines below $9.50.
Investor Verification Checklist
- Verify the closing of the $6.0 million private placement on or before January 9, 2014.
- Confirm the filing and effectiveness of the registration statement covering the new ADSs and warrants.
- Monitor future capital raising activities to assess if the $9.50 anti-dilution trigger is activated.
- Track the progress of Phase III clinical trials for RHB-104 and RHB-105 as the primary use of proceeds.